Harrow Announces Availability of VEVYE® (Cyclosporine Ophthalmic Solution) 0.1%, the First and Only Cyclosporine-Based Product Indicated for Treating Both Signs and Symptoms of Dry Eye Disease

Stock Information for Harrow Inc Com

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Harrow Inc Com

Harrow Will Release First Quarter 2024 Financial Results After Market Close on May 13, 2024
Melt Pharmaceuticals Closes $24 Million Series B Preferred Stock Financing
Harrow Announces Fourth Quarter and Year-End 2023 Financial Results
Harrow Will Release Fourth Quarter and Year-End 2023 Financial Results After Market Close on March 19, 2024
Harrow Announces New Appointments to its Board of Directors
Melt Pharmaceuticals Provides Corporate Update
Harrow Partners with Leading Healthcare Market Access Technology Platforms
Harrow Completes Transfer of the TRIESENCE® New Drug Application

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.